Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IncobotulinumtoxinA Clear all
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

NCT00406367
View directory record Official record
Conditions
Blepharospasm
Interventions
incobotulinumtoxinA (Xeomin), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Sep 30, 2026, 3:06 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Encino, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

NCT00512135
View directory record Official record
Conditions
Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Sep 30, 2026, 3:06 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 30, 2026, 3:06 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Early BOTOX After Spinal Cord Injury

NCT06793683
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Bladder chemodenervation (Botox), Bladder Sham (Saline) Injection Procedure
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Sep 30, 2026, 3:06 PM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 30, 2026, 3:06 PM EDT
Active, not recruiting Phase 2 Interventional

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
incobotulinumtoxin A
Drug
Lead sponsor
Zel Skin and Laser Specialists
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand

NCT02107261
View directory record Official record
Conditions
Dystonia
Interventions
incobotulinumtoxin A, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 30, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Results available

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

NCT01931865
View directory record Official record
Conditions
Pain
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 30, 2026, 3:06 PM EDT
Recruiting Phase 2 Interventional

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 30, 2026, 3:06 PM EDT
Completed No phase listed Observational

Phase IV-Cervical Dystonia-INTEREST IN CD2

NCT01753349
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Elkridge, Maryland • Boston, Massachusetts • Southfield, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 30, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Results available

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

NCT04965311
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 30, 2026, 3:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Evaluation of Combination Treatment With the Ulthera System

NCT02444169
View directory record Official record
Conditions
Skin Laxity
Interventions
Ultherapy, Incobotulinumtoxin A, Radiesse, Belotero Balance
Device · Drug
Lead sponsor
Ulthera, Inc
Industry
Eligibility
25 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Laguna Beach, California • San Diego, California • Coral Gables, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Sep 30, 2026, 3:06 PM EDT
Completed No phase listed Observational

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

NCT01287247
View directory record Official record
Conditions
Cervical Dystonia, Blepharospasm
Interventions
Xeomin®
Biological
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
70
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

NCT00945295
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Botulinum toxin type A, BoNT-A, Rehabilitation Therapy
Drug · Other
Lead sponsor
JoAnn Harnar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

NCT01486264
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Xeomin®
Biological
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Fountain Valley, California • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Sep 30, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

NCT06604832
View directory record Official record
Conditions
Skin Aging, Skin Wrinkling
Interventions
PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo)
Drug
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 30, 2026, 3:06 PM EDT